Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|January 2, 2013
- Pharmaceutical Technology-01-02-2013
- Volume 37
- Issue 1
Pharmaceutical Technology, January 2013 Issue (PDF)
The Future of Pharma Manufacturing
Advertisement
Articles in this issue
almost 14 years ago
Standards-Setting Activities on Impuritiesalmost 14 years ago
A Look Ahead at Manufacturing and Regulationalmost 14 years ago
The Transformation to Process-Centered Organizationalmost 14 years ago
The Latest in IT/Automation/Process controlalmost 14 years ago
A Look Ahead for 2013almost 14 years ago
Pharma Conversation & Communityalmost 14 years ago
Strategies in API Scale Upalmost 14 years ago
Report from Brazil January 2013almost 14 years ago
X-ray Powder Diffraction Pattern Indexing for Pharmaceutical Applicationsalmost 14 years ago
Offshoring BiomanufacturingAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
5